These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 8463449)

  • 1. A naturalistic follow-up of panic patients after short-term pharmacologic treatment.
    Munjack DJ; Brown RA; Cabe DD; McDowell DE; Baltazar PL
    J Clin Psychopharmacol; 1993 Apr; 13(2):156-8. PubMed ID: 8463449
    [No Abstract]   [Full Text] [Related]  

  • 2. Discontinuation of alprazolam after long-term treatment of panic-related disorders.
    DuPont RL; Swinson RP; Ballenger JC; Burrows GD; Noyes R; Rubin RT; Rifkin A; Pecknold JC
    J Clin Psychopharmacol; 1992 Oct; 12(5):352-4. PubMed ID: 1479053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diazepam versus alprazolam for the treatment of panic disorder.
    Noyes R; Burrows GD; Reich JH; Judd FK; Garvey MJ; Norman TR; Cook BL; Marriott P
    J Clin Psychiatry; 1996 Aug; 57(8):349-55. PubMed ID: 8752017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three-year follow-up of patients with panic disorder after short-term treatment with alprazolam and imipramine.
    Lepola UM; Rimón RH; Riekkinen PJ
    Int Clin Psychopharmacol; 1993; 8(2):115-8. PubMed ID: 8345160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Personality dimensions in panic disorder before and after effective treatment.
    Starcevic V; Uhlenhuth EH
    Anxiety; 1996; 2(2):95-8. PubMed ID: 9160608
    [No Abstract]   [Full Text] [Related]  

  • 6. Abrupt discontinuation of alprazolam and cognitive style in patients with panic disorder: early effects on mood, performance, and vital signs.
    Uhlenhuth EH; Starcevic V; Qualls C; Antal EJ; Matuzas W; Javaid JI; Barnhill J
    J Clin Psychopharmacol; 2006 Oct; 26(5):519-23. PubMed ID: 16974197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Method for assessing the duration of therapeutic action and milligram equivalence of anxiolytics.
    Sheehan DV; Raj AB; Harnett-Sheehan K; Dorotheo J; Sheehan MF; Trehan R; Knapp E; Swiontek A; Coleman B
    Anxiety; 1996; 2(1):40-6. PubMed ID: 9160598
    [No Abstract]   [Full Text] [Related]  

  • 8. The speed of onset of action of alprazolam-XR compared to alprazolam-CT in panic disorder.
    Sheehan DV; Sheehan KH; Raj BA
    Psychopharmacol Bull; 2007; 40(2):63-81. PubMed ID: 17514187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of alprazolam discontinuation with and without cognitive behavior therapy in panic disorder.
    Bruce TJ; Spiegel DA; Gregg SF; Nuzzarello A
    Am J Psychiatry; 1995 Aug; 152(8):1156-60. PubMed ID: 7625463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alprazolam premedication and 35% carbon dioxide vulnerability in panic patients.
    Pols H; Verburg K; Hauzer R; Meijer J; Griez E
    Biol Psychiatry; 1996 Nov; 40(9):913-7. PubMed ID: 8896779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does cognitive behavior therapy assist slow-taper alprazolam discontinuation in panic disorder?
    Spiegel DA; Bruce TJ; Gregg SF; Nuzzarello A
    Am J Psychiatry; 1994 Jun; 151(6):876-81. PubMed ID: 8184997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medication discontinuation in panic disorder.
    Ballenger JC; Pecknold J; Rickels K; Sellers EM
    J Clin Psychiatry; 1993 Oct; 54 Suppl():15-21; discussion 22-4. PubMed ID: 8262887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term follow-up after a drug trial for panic disorder.
    Katschnig H; Amering M; Stolk JM; Klerman GL; Ballenger JC; Briggs A; Buller R; Cassano G; Garvey M; Roth M
    Br J Psychiatry; 1995 Oct; 167(4):487-94. PubMed ID: 8829718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy studies of alprazolam in panic disorder.
    Spiegel DA
    Psychopharmacol Bull; 1998; 34(2):191-5. PubMed ID: 9640999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship of alprazolam and clonazepam dose to steady-state concentration in plasma.
    Labbate LA; Pollack MH; Otto MW; Tesar GM; Rosenbaum JF
    J Clin Psychopharmacol; 1994 Aug; 14(4):274-6. PubMed ID: 7962684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comorbid cannabis use and panic disorder: short term and long term follow-up study.
    Dannon PN; Lowengrub K; Amiaz R; Grunhaus L; Kotler M
    Hum Psychopharmacol; 2004 Mar; 19(2):97-101. PubMed ID: 14994319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Issues in the assessment of treatment response in panic disorder with special reference to fluvoxamine.
    Ninan PT
    J Clin Psychiatry; 1997; 58 Suppl 5():24-31. PubMed ID: 9184624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anxiolytic therapy with alprazolam increases muscle sympathetic activity in patients with panic disorders.
    Béchir M; Schwegler K; Chenevard R; Binggeli C; Caduff C; Büchi S; Buddeberg C; Lüscher TF; Noll G
    Auton Neurosci; 2007 Jul; 134(1-2):69-73. PubMed ID: 17363337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two cases of alprazolam-induced hyperprolactinemia in patients with panic disorder.
    Shioiri T; Kita N; Takahashi S
    Int Clin Psychopharmacol; 1996 Jun; 11(2):149-52. PubMed ID: 8803653
    [No Abstract]   [Full Text] [Related]  

  • 20. Predictors of response to alprazolam and placebo in patients with panic disorder.
    Woodman CL; Noyes R; Ballenger JC; Lydiard RB; Sievers G; Mihalko D
    J Affect Disord; 1994 Jan; 30(1):5-13. PubMed ID: 8151049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.